Faculty profile

Dawn Maze

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Toronto

Dawn Maze

Assistant Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
88 publications in the last five years, latest in 2026.
Senior (last) author on 14 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2015.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

157

Publications

1,034

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Autologous Stem Cell Transplant Bleeding Cost-Effectiveness Analysis Patient Centred Outcomes Platelet Transfusions Randomized Controlled Trial Tranexamic Acid Hematopoieitic Stem Cell Transplantation

Latest papers

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.
Haematologica · 2026
A stem and progenitor cell–derived gene expression signature is prognostic for survival in myelofibrosis
Blood · 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)
The Lancet Regional Health. Americas · 2026

All 157 publications

Latest funding

Platelet Transfusions in Hematopoietic Stem cell Transplantation - The PATH Study
CIHR · 2015 · Principal investigator
$213,400
Safety and Efficacy of a Therapeutic Platelet Transfusion Strategy in Outpatients
CIHR · 2011 · Co-investigator
$150,031

All 2 grants and awards

From the 150 most recent of 157 publications.

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Murphy T, Zhang B, Zhang T, King I, Capo-Chichi J-M, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD

Haematologica20266 citationsOpen Access

DOI: 10.3324/haematol.2025.287777

A stem and progenitor cell–derived gene expression signature is prognostic for survival in myelofibrosis

Jessie J.F. Medeiros, Andy G.X. Zeng, Suraj Bansal, H. Kim, Michelle Chan Seng Yue, Tristan Woo, Jessica L. McLeod, Sagar P. Kothari, Andrea Arruda, Hubert Tsui, Jaime O. Claudio, Dawn C. Maze, Hassan Abdulmaoula Sibai, M. D. Minden, James A. Kennedy, Christopher A. Famulare, Raajit K. Rampal, Jean C.Y. Wang, John Edgar Dick, V. Gupta

Blood20264 citationsOpen Access

DOI: 10.1182/blood.2025030094 PMID: 41481381

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)

Reeves BN, Chaer FE, Foltz L, Tashi T, Abu-Zeinah G, Qin A, Lucas J, Halpern AB, Maze D, Safah H

The Lancet Regional Health. Americas20261 citations

DOI: 10.1016/j.lana.2026.101529

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Rajendra A, Smith E, Atenafu EG, Bankar A, Chan S, Davidson M, Gupta V, Minden MD, Perusini MA, Richard-Carpentier G, Schimmer A, Schuh AC, Sibai H, Yee K, Maze D

Clinical lymphoma, myeloma & leukemia2026Senior author

DOI: 10.1016/j.clml.2025.10.016 PMID: 41238480

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT

Donna Zhe Sian Eng, Fatime Khadadah, María Agustina Perusini, Eshrak Al Shaibani, Eshetu G. Atenafu, Aniket Bankar, Marta Beata Davidson, Guillaume Abou Richard-Carpentier, Dawn C. Maze, Karen W L Yee, Aaron David Schimmer, Vikas Gupta, Steven T. F. Chan, Dennis Dong Hwan Kim, André Silvestri Schuh, Hassan Abdulmaoula Sibai

Preprints.org2026Open Access

DOI: 10.20944/preprints202601.0593.v1

Myeloproliferative neoplasms in the young: unique disease patterns and therapeutic strategies

Aarya Murali, James T. England, Dawn C. Maze

Current Opinion in Hematology2026Senior author

DOI: 10.1097/moh.0000000000000910 PMID: 41556184

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Eng DZS, Khadadah F, Perusini MA, Al-Shaibani E, Atenafu EG, Bankar A, Davidson M, Richard-Carpentier G, Maze D, Yee K, Schimmer A, Gupta V, Chan S, Kim DDH, Schuh A, Minden M, Sibai H

Current oncology (Toronto, Ont.)2026Open Access

DOI: 10.3390/curroncol33020127 PMID: 41744891

Extramedullary AML: Clinical and Molecular Features.

Morgenstern Y, Andrews C, Atenafu EG, Chan S, Gupta V, Minden MD, Maze D, Schimmer A, Schuh A, Yee K, Sibai H

Cancers2026Open Access

DOI: 10.3390/cancers18091362 PMID: 42122157

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study

Ruben A. Mesa, Harinder Singh Gill, Lei Zhang, Jie Jin, Keita Kirito, Norio Komatsu, Albert Qin, Zhijian Xiao, Tsewang Tashi, Kazuya Shimoda, Kohshi Ohishi, Suning Chen, Xuelan Zuo, Shuichi Shirane, Yu Hu, Sujiang Zhang, Yi Wang, Katsuto Takenaka, Michiko Ichii, Na Xu, Lee-Yung Shih, Ken‐Hong Lim, Sung‐Eun Lee, Sung Hwa Bae, Winnie Z.Y. Teo, Dawn C. Maze, Stephen T. Oh, Prithviraj Bose, Toshiaki Sato, Oleh Zagrijtschuk, et al. (34 authors)

The Lancet Haematology202515 citationsOpen Access

DOI: 10.1016/s2352-3026(25)00264-9 PMID: 41193116

ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera

Mascarenhas J, Mascarenhas J, Bose P, Hillis C, Yacoub A, El Chaer F, Maze D, Abu-Zeinah G, Qin A, Priego V

Acta Haematologica20258 citations

DOI: 10.1159/000544818

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Dawn Maze

Research

Latest papers

Latest funding

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

A stem and progenitor cell–derived gene expression signature is prognostic for survival in myelofibrosis

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT

Myeloproliferative neoplasms in the young: unique disease patterns and therapeutic strategies

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Extramedullary AML: Clinical and Molecular Features.

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study

ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera

Platelet Transfusions in Hematopoietic Stem cell Transplantation - The PATH Study

Safety and Efficacy of a Therapeutic Platelet Transfusion Strategy in Outpatients

Frequent collaborators

Aaron Schimmer

Steven Chan

Mark Minden

Tracy Stockley

Vikas Gupta

Maria Perusini

Hassan Sibai

Mitchell Sabloff

Christopher Bredeson

David Allan

Karen Yee

Lothar Huebsch

Aniket Bankar

Jonas Mattsson

Natasha Kekre

Brian Leber

Christopher Hillis

Scott Bratman

Harold Atkins

Jason Tay

Ann Malinowski

Dennis Kim

Prakesh Shah

Natasha Szuber

Waleed Sabry

Christian Houbois

Eugene Yu